Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 79.41% | 51.15% | 64.00% | 40.36% | 28.18% |
| Total Depreciation and Amortization | -34.19% | -20.58% | 1,659.85% | 1,728.41% | 1,813.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.53% | -17.70% | -45.49% | 5.26% | 13.14% |
| Change in Net Operating Assets | -678.00% | -311.21% | -153.63% | -127.35% | -94.33% |
| Cash from Operations | 48.54% | 45.26% | 47.15% | -11.48% | 38.24% |
| Capital Expenditure | -- | -- | 100.00% | -371.11% | 20.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 126.75% | 104.97% | 78.84% |
| Cash from Investing | -- | -- | 125.80% | 103.93% | 77.88% |
| Total Debt Issued | 148.16% | -31.51% | -68.78% | -139.72% | -140.26% |
| Total Debt Repaid | -106.65% | 69.99% | 63.44% | 81.35% | 81.35% |
| Issuance of Common Stock | 32.40% | -6.81% | -14.08% | 656.80% | -73.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -98.53% | -75.94% | -70.07% | -- | -- |
| Cash from Financing | -33.01% | -42.41% | -52.89% | 38.12% | -58.41% |
| Foreign Exchange rate Adjustments | -14.68% | 9,904.76% | -90.28% | 415.59% | 186.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.88% | 121.78% | 58.66% | 100.02% | 30.94% |